ARTICLE | Clinical News
AGIX-4207: Began Phase I testing
February 26, 2001 8:00 AM UTC
AtheroGenics Inc. (AGIX), Atlanta, Ga. Product: AGIX-4207 Business: Auoimmune/Inflammation Therapeutic category: Immune modulation Target: TNF-alpha Description: Oral modulator of TNF-alpha Indicati...